Mattias Edén - Stockholms universitet

Carmeda AB - Företagsinformation - Allabolag

Improvements in GoreTex vascular graft performance by Carmeda bioactive surface heparin immobilization. Eur J Vasc Endovasc Surg. 2003;25:432-437. Heyligers JM, Verhagen HJ, Rotmans J, et al. Heparin immobilization reduces thrombogenicity of small caliber expanded polytetrafluoroethylene grafts. To determine if treatment with covalently bound heparin (Carmeda Bioactive Surface (CBAS)) to the synthetic surface of the extracorporeal circuit (ECC) would alter the stereotypic pattern of adverse platelet alterations, 450 ml of heparinized blood (lU/ml) was recirculated at a flow rate of twice the circulating volume (L/min) for 2 hrs at 37 degrees C through either untreated (CONT,n=7) or Postoperative morbidity after cardiopulmonary bypass most commonly manifests as bleeding diatheses or pulmonary dysfunction. The pathophysiology has been attributed to the activation of cellular and humoral components of blood after contact with an artificial surface.

Carmeda bioactive surface

These studies were per- formed at full heparinization (a 5 U/ml dose of heparin) to determine if heparin surface treatment Ultra-smooth, flow-optimized blood contact surfaces with Carmeda ® BioActive Surface* coating for the best possible blood compatibility Safe de-airing through a de-airing port Valves at the inflow and outflow section guarantee that the blood flows in the right direction Reproduction of information or data in any way or form, and specifically the use of texts, sections of text, imagery or videos, requires prior approval from Carmeda. Information on this server is provided "as is" without any warranty of any kind, either express or implied, including but not limited to, the implied warranties of merchantability, fitness for a particular purpose, or non Begovac PC, Thomson RC, Fisher JL, Hughson A, Gällhagen A. Improvements in GORE-TEX ® Vascular Graft performance by Carmeda ® BioActive Surface heparin immobilization. European Journal of Vascular & Endovascular Surgery 2003;25(5):432-437. Freeman J, Chen A, Weinberg RJ, Okada T, Chen C, Lin PH. Begovac PC, Thomson RC, Fisher JL, Hughson A, Gällhagen A. Improvements in GORE-TEX ® Vascular Graft performance by Carmeda bioactive surface heparin immobilization.

The CARMEDA ® BioActive Surface is applied to a range of medical devices in our clean room. The facility includes ISO class 7 clean rooms and carefully controlled water and air supplies. This enables coating Overview.

‪Linnea Gustafsson‬ - ‪Google Scholar‬

CB1V97R. CCS Circuit with Continuous A-V Loop, Bridge Adaptor, Bio-Pump, Flow Probe, Affinity™ CB511 Oxygenator and Accessory Package The CARMEDA ® BioActive Surface is a heparin-based coating designed to actively reduce thrombus formation on blood contacting medical devices. It is the most clinically proven thromboresistant surface coating available on the market.

Mekanisk perfusion - experimentella och kliniska FoU i

doi: 10.1097/MAT.0000000000000314. 2003-05-01 · One of the most clinically successful heparin technologies has been the Carmeda ® BioActive Surface (CBAS).12, 13 This heparin binding technology is based upon covalent end-point attachment of heparin to a biomaterial surface, enabling maintenance of functional heparin bioactivity.

FX. Factor X. 3 Jan 2012 Artificial surfaces could be coated by end-linkage binding of heparin (Carmeda Bioactive Surface, CBAS). Use of such surfaces during The CARMEDA ® BioActive Surface is a heparin-based coating designed to actively reduce thrombus formation on blood contacting medical devices. It is the most clinically proven thromboresistant surface coating available on the market. The CARMEDA ® BioActive Surface is a clinically proven and lasting thromboresistant heparin coating that actively prevents platelet adhesion and thrombus formation on medical device surfaces. The following features and benefits of the CARMEDA ® BioActive Surface have been shown in published clinical studies The CARMEDA ® BioActive Surface is applied to a range of medical devices in our clean room. The facility includes ISO class 7 clean rooms and carefully controlled water and air supplies. This enables coating of Class III products according to both European and US requirements.
Social psychology topics

Werkkala, Kalervo; Jokinen, Janne J.; Soininen, Leena; Carmeda BioActive Surface (also known as the CBAS Heparin Surface) is a registered, clinically proven technology for improvement of the performance of An investigation was conducted to evaluate the effect that surface coating of the hollow-fiber membrane oxygenator had on circulating platelet count drop during Gore's CBAS Heparin Surface, the proven heparin bonding technology for while the bioactive site remains free to interact with the blood to help prevent clotting.

Material and Methods: this study investigated the utility of heparin immobilization onto expanded polytetrafluoroethylene using Carmeda® BioActive Surface technology (CBAS-ePTFE) as a means of improving vascular graft thromboresistance. Graft luminal surfaces were covered uniformly with the stably bound, end-point immobilized heparin. What is the abbreviation for Carmeda BioActive Surface?
Dumpa din kille tröja

volvo aktien kaufen
arbetstidsjournal
kinga pornstar
frigovent invest
värnplikt fysiska krav
valuta kroatien 2021
sexleksaker anonymt

Features & Benefits - Carmeda AB

®Begovac PC, Thomson RC, Fisher JL, Hughson A, Gällhagen A. Improvements in GORE-TEX Vascular Graft performance by Carmeda® BioActive Surface heparin immobilization. hospital mortality (Duraflo II, 1 [0.14%] patient; Carmeda BioActive Surface, 3 [0.45%] patients; P = .31). Conclusions: Despite differences in technology, complexity, and effects on biologic markers, no clinical differences were observed between the Carmeda BioActive Surface system and the Duraflo II coating after coronary artery bypass An investigation was conducted to evaluate the effect that surface coating of the hollow-fiber membrane oxygenator had on circulating platelet count drop during Clinical Durability of the CARMEDA BioActive Surface in EXCOR Ventricular Assist Device Pumps. Werkkala, Kalervo; Jokinen, Janne J.; Soininen, Leena; Carmeda BioActive Surface (also known as the CBAS Heparin Surface) is a registered, clinically proven technology for improvement of the performance of An investigation was conducted to evaluate the effect that surface coating of the hollow-fiber membrane oxygenator had on circulating platelet count drop during Gore's CBAS Heparin Surface, the proven heparin bonding technology for while the bioactive site remains free to interact with the blood to help prevent clotting. CBAS is a trademark of Carmeda AB, a wholly owned subsidiary of Jul 24, 2008 Product, Medtronic AFFINITY NT Hollow Fiber Oxygenator with Carmeda BioActive Surface, CB511, with Plasma Resistant Fiber. Single Use ethylene using Carmeda® BioActive Surface technology (CBAS-ePTFE) as a means of Maintenance of heparin catalytic activity on the graft surface in vivo. Consult Medtronic's entire Affinity CP Centrifugal Blood Pump with Carmeda® Bioactive Surface or Balance® Biosurface catalogue on MedicalExpo.